Pericarditis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:16:17 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pericarditis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the safety and effectiveness of KPL-387 in patients with well-controlled recurrent pericarditis https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-kpl-387-in-patients-with-well-controlled-recurrent-pericarditis/ Wed, 29 Apr 2026 15:09:34 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-kpl-387-in-patients-with-well-controlled-recurrent-pericarditis/ This study focuses on Recurrent Pericarditis, a condition where the thin sac surrounding the heart becomes inflamed repeatedly. The research aims to evaluate the efficacy and safety of transitioning from standard treatments to a single medication called KPL-387. This medication is administered via subcutaneous injection, which is a method of delivering medicine through a small needle just under the skin.

Participants in the study will undergo a process to change from their current standard therapies to KPL-387 monotherapy, meaning the use of only one drug. The study includes a long-term extension period to observe how well the medication works over an extended duration. Throughout the course of the study, the focus is on monitoring how well the condition is managed and identifying any potential side effects during the transition and long-term use.

]]> A study to evaluate the safety and effectiveness of VTX2735 sodium in patients with recurrent pericarditis https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-vtx2735-sodium-in-patients-with-recurrent-pericarditis/ Wed, 29 Apr 2026 15:09:13 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-vtx2735-sodium-in-patients-with-recurrent-pericarditis/ This study focuses on individuals living with Recurrent Pericarditis, a condition where the thin sac surrounding the heart becomes inflamed multiple times. The research aims to evaluate the safety and tolerability of a new medication called VTX2735. This medication is administered as an oral modified-release tablet, which is a type of pill designed to release the medicine into the body at a controlled rate over a period of time.

During the study, participants will receive the study drug to observe how it affects the body and how well it is tolerated. The investigation will monitor how the medicine moves through the system and its impact on certain biological markers, such as hs-CRP, which is a blood test used to measure inflammation in the body. The process involves regular observations to track any changes in symptoms or physical reactions following the administration of the treatment.

]]> Study of cannabidiol (CardiolRx) in patients with recurrent pericarditis after stopping IL-1 blocker treatment https://clinicaltrials.eu/trial/study-on-the-effects-of-cardiolrx-and-placebo-in-patients-with-recurrent-pericarditis-after-stopping-il-1-blocker-therapy/ Wed, 29 Apr 2026 15:04:44 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-cardiolrx-and-placebo-in-patients-with-recurrent-pericarditis-after-stopping-il-1-blocker-therapy/ This clinical trial focuses on patients with recurrent pericarditis, a condition where the protective covering around the heart becomes inflamed repeatedly. The study will test a medication called CardiolRx, which contains cannabidiol as its active ingredient, in patients who are currently being treated with IL-1 blockers (medications that reduce inflammation) and are ready to stop this treatment.

The purpose of this research is to determine if patients who are dependent on IL-1 blockers can successfully stop their current treatment while taking CardiolRx without experiencing another episode of pericarditis. The study will compare CardiolRx with placebo over a period of 24 weeks (6 months). Both CardiolRx and the placebo will be given as oral solutions.

During the study, participants will be monitored for signs of pericarditis returning, which includes checking for chest pain and measuring levels of C-Reactive Protein (a substance in the blood that indicates inflammation) in their blood. The medication will be given daily, with doses calculated based on the patient’s weight, up to a maximum of 20 milligrams per kilogram per day.

]]> Study Comparing Anakinra and Prednisone for Children with Colchicine-Resistant Recurrent Pericarditis https://clinicaltrials.eu/trial/study-comparing-anakinra-and-prednisone-for-children-with-colchicine-resistant-recurrent-pericarditis/ Wed, 29 Apr 2026 14:26:27 +0000 https://clinicaltrials.eu/trial/study-comparing-anakinra-and-prednisone-for-children-with-colchicine-resistant-recurrent-pericarditis/ This clinical trial is focused on studying a condition called recurrent pericarditis, which is a repeated inflammation of the thin sac-like covering of the heart. This condition can occur without a known cause or as a result of heart procedures and does not respond well to common treatments like colchicine and non-steroidal anti-inflammatory drugs (NSAIDs). The trial is specifically for children who have experienced a relapse of pericarditis and have not had success with these initial treatments.

The study will compare two treatments: Anakinra, which is given as an injection under the skin, and Prednisone, a type of steroid taken in tablet form. Anakinra is a medication that helps reduce inflammation by blocking certain proteins in the body, while Prednisone is a corticosteroid that also helps to reduce inflammation and suppress the immune system. The main goal of the study is to determine if Anakinra is more effective than steroids in controlling the disease and preventing further flare-ups in children who have not responded to first-line treatments.

Participants in the study will receive either Anakinra or Prednisone for a period of up to 24 weeks. The study will monitor the response to treatment, including the complete response of disease flare at day 7 and the lack of relapse at month 3. Other aspects such as the time it takes to control the flare, the number of flare-ups during follow-up, and the overall quality of life will also be observed. Safety will be closely monitored throughout the study to record any side effects. The study aims to provide valuable information on the effectiveness and safety of these treatments for children with recurrent pericarditis.

]]>